Nilogen Oncosystems is a CLIA-certified contract research organization offering immuno-oncology drug development services for pharmaceutical and biotechnology companies. Our proprietary 3D ex vivo drug testing platform utilizes fresh patient tumor tissue with intact tumor immune microenvironment to accurately assess therapeutic efficacy of immuno-oncology drugs and to develop rationale drug combination strategies. Through comprehensive correlative studies between ex-vivo drug responses and clinical, cellular and molecular aspects of tumors, Nilogen aims to develop companion diagnostics to facilitate biomarker-driven drug development efforts and personalized medicine while reducing the cost and risk of bringing a new drug to market.
Nilogen To Present At AACR 2023
Apr 07, 2023
Posted by Nilogen Oncosystems
Unveiling the Power Within: Tumoroids for Translational IO Drug Discovery & Development
Jun 21, 2023